Adjuvant chemotherapy in colorectal cancer
Evidence Summaries Level of Evidence = A
Adjuvant chemotherapy increases disease-free survival although no overall survival in patients with stage II colon cancer.
A Cochrane review 1 included 33 randomized trials and 17 meta-analyses containing data on stage II colon cancer patients undergoing adjuvant therapy versus surgery alone. The participants in the trials were patients with completely resected colon (n=7,731) or rectal (n=7,600) cancers. With regards to the effect of adjuvant therapy on stage II colon cancer, the pooled relative risk ratio for overall survival was 0.96 (95% CL 0.88 to 1.05). With regards to disease-free survival, the pooled relative risk ratio was 0.83 (95% Cl 0.75 to 0.92).
1. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008;(3):CD005390. [PMID:18646127]
Copyright © 2017 Duodecim Medical Publications Limited.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.